Harmonic Drive Systems (HSYDF) Was Downgraded to a Sell Rating at Jefferies
Hold Rating on Harmonic Drive Systems Amidst Sales Decline and Uncertain Recovery
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
Third Harmonic Bio Analyst Ratings
Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Harmonic Price Target Raised to $20.00/Share From $14.00 by Barclays
Barclays Maintains Overweight on Harmonic, Raises Price Target to $20
Needham Maintains Harmonic(HLIT.US) With Buy Rating, Maintains Target Price $18
Buy Rating Affirmed for Harmonic on Strong Q2 Performance and Market Leadership in VCMTS Software
Harmonic Analyst Ratings
Needham Reiterates Buy on Harmonic, Maintains $18 Price Target
Barclays Keeps Their Buy Rating on Harmonic (HLIT)
Harmonic Analyst Ratings
Rosenblatt Maintains Buy on Harmonic, Maintains $18 Price Target
Third Harmonic Bio Analyst Ratings
Stifel Initiates Coverage On Third Harmonic Bio With Buy Rating, Announces Price Target of $23
What 5 Analyst Ratings Have To Say About Harmonic
Needham Reiterates Buy on Harmonic, Maintains $18 Price Target
Harmonic Analyst Ratings